Purpose: This study aims to explore the association of CpG island methylator phenotype (CIMP) involving tumor suppressor genes on short arm of chromosome 3 (3p) with increased risk of non-small cell lung cancer (NSCLC).
pidemiological evidence has documented that lung cancer has markedly increased incidence and mortality over the past decade in China. 1 Because at least 75% of patients with lung cancer have evidence of regional or distant metastasis at the time of diagnosis, the overall 5-year survival rate of lung cancer is very poor. 2 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases and consisting mainly of adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. 3 It has been suggested that NSCLC could result from accumulation of multiple genetic or epigenetic changes, including DNA methylation and histone acetylation 4 and microRNA. 5, 6 Our recent studies provide support for the notion that DNA methylation could underlie epigenetically inactivation of tumor suppressor genes (TSGs) on short arm of chromosome 3 (3p) in NSCLC, 7 and CpG island methylator phenotype (CIMP) involving TSGs on 3p could be one of the frequent epigenetic events in carcinogenesis of NSCLC. 8 Multiple investigations have evaluated DNA methylation changes present in NSCLC, elucidating a wide range of methylation frequencies for a variety of genes. 9 -13 A majority of studies have compared the methylation aberrations occurred in NSCLC with those presented in the paired paracancerous lung tissues from the same patient. 14 More recently, Brock et al. 15 found aberrant patterns of promoter methylation of APC, RASSF1A, p16, and CDH13 associated with early recurrence in stage I NSCLC. Taken together, these experimental data are beneficial in identifying a panel of cancer-specific methylation markers for early detection and prevention and targeted treatment of NSCLC. Importantly, more particular attention was paid to assessing synchronous methylation of multiple cancer-related genes (termed CIMP) and its implications to patients with NSCLC. 16, 17 Following the recently published reports on the presence of CIMP in NSCLC, 16, 17 for the first time, we shed light on the presence of chromosome 3p-involved CIMP (3pCIMP) that might play an important role in tumorigenesis of NSCLC. 8 Although there is accumulating evidence suggesting that somatic epigenetic changes of putative TSGs contribute to carcinogenesis of NSCLC 14 and DNA hypermethylation frequently occurs in peripheral blood mononuclear cell (PBMC) from colorectal and lung cancer patients, 18, 19 little is known about an association of PBMC 3pCIMP with the predisposition to developing NSCLC.
In this study, we tested hypothesis that some individuals carrying PBMC 3pCIMP are more susceptible to developing NSCLC. First, to investigate whether 3pCIMP status could play an important role in NSCLC cell proliferation, we examined 3pCIMP status in four NSCLC cell lines before and after the demethylating treatment. Then, we subjected bisulfite-modified DNA of PBMC from 80 NSCLC patients and 80 controls to analysis of 3pCIMP status. The results suggest that 3pCIMP could occur frequently in PBMC from Chinese population, indicating that PBMC 3pCIMP plays an important role in predisposition to NSCLC.
METHODS

NSCLC Cell Lines and Specimens
Four NSCLC cell lines (SPC-A-1, A549, 95-D, and LTEP-a-2) purchased from Shanghai Institute of Biochemistry and Cell Biology were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco-Invitrogen Inc.) with 10% fetal bovine serum (Gibco-Invitrogen Inc., Grand Island, NY) and incubated at 37°C in a humid atmosphere of 5% CO 2 . These NSCLC cell lines are from lung adenocarcinoma cells.
A total of 80 blood specimens were obtained after informed consent from patients who were diagnosed as primary NSCLC in the First Affiliated Hospital of Soochow University between January 2005 and March 2008. Pathologic stages for NSCLC patients were determined according to the Revised International System for Staging Lung Cancer. 20 None of NSCLC patients had received either radiotherapy or chemotherapy before blood sampling. In addition to NSCLC blood samples, 80 blood samples were also collected from individuals with no history of cancer as controls, which were randomly selected from the same geographic region, and their ages were in the similar range as the cancer patients. This research was approved to perform by the Academic Advisory Board of Soochow University.
PBMC was isolated by centrifugation at 3500 rpm for 20 minutes after blood sampling. 21 Genomic DNA was isolated from NSCLC cell lines and the samples according to standard proteinase K digestion and phenol-chloroform extraction.
Bisulfite Modification
Genomic DNA was treated with sodium bisulfite before methylation analysis according to the CpGenome Fast DNA Modification Kit (Chemicon International, Inc.). The procedure for bisulfite modification was described in our previously published article. 8 Briefly, 1.0 g of DNA in a volume of 100 l water were denatured for 10 minutes at 37°C by addition of 7 l of freshly prepared 3 M NaOH. Then 550 l of freshly prepared DNA Modification Reagent (pH 5.0) was added and mixed well. The mixture was incubated at 55°C for 20 hours. After adding 750 l of binding buffer, we purified the modified DNA with spin columns. Desulphonation was completed on the column by addition of 50 l of freshly prepared 20 mM NaOH/90% EtOH. Finally, DNA was eluted with 30 to 45 l of elution buffer and stored at Ϫ20°C until analyzing.
Methylation-Specific PCR
DNA methylation was determined using methylation-specific polymerase chain reaction (PCR) (MSP) described elsewhere. 22 MSP can differentiate methylated alleles from unmethylated ones of an interested gene after treatment with sodium bisulfite. Primer sequences for MSP analysis of RAR-B, SEMA3B, RASSF1A, BLU, and FHIT were reported previously [23] [24] [25] [26] [27] except for that of hOGG1 was designed by ourselves using Methyl Primer Express Software version 1.0 (Applied Biosystem Inc, Forster City, CA). 8 All the cycling conditions of PCR consisted of an initial denaturation at 95°C for 5 minutes, followed by 35 cycles of 94°C for 30 seconds, various annealing temperature for 45 seconds, and 72°C for 1 minute 15 seconds. The expected PCR products were revealed by electrophoresis and visualized with ethidium bromide staining. SPC-A-1 and A549 NSCLC cell lines were used as positive controls for hOGG1, RAR-B, SEMA3B, BLU, and FHIT; and for RASSF1A, respectively. But distilled water and unbisulfited DNA were served as negative controls. 7 
DNA Demethylation of NSCLC Cell Lines
DNA demethylation was performed on NSCLC cells by treatment with 5-aza-deoxycytidine (5-aza-CdR) (Sigma-Aldrich Inc, St. Louis, MO). Briefly, NSCLC cells were seeded at a density of 5 ϫ 10 4 cells in RPMI 1640 containing 10% fetal bovine serum on day 1 and allowed to grow under standard tissue culture conditions. On days 2, 4, and 6, the medium was changed to serum-free RPMI 1640 containing 5 M 5-aza-CdR. On days 3, 5, and 7, the medium was changed to drug-free and serum-free RPMI 1640. On days 1, 5, and 7, the cells were harvested for analysis of DNA methylation.
MTT Assay
Proliferation of NSCLC cells before and after treatment of demethylation agent 5-aza-CdR was assessed with the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma-Aldrich, Inc) method. Cells were seeded in 96-well plates at a density of 5 ϫ 10 4 cells/well and cultured under standard tissue culture conditions for 24 hours. On days 2, 4, and 6, the medium was changed to serum-free RPMI 1640 containing 5 M 5-aza-CdR. On days 1, 5, and 7, 20 l of 5 mg/ml MTT were added, and the cells were incubated for 5 hours at 37°C. One hundred microliters of dimethyl sulfox-ide were quickly added to all wells and mixed thoroughly, so that the dark blue crystals dissolved effectively. Absorbance was measured at the wavelength of 550 nm. This experiment was repeated three times. All data represent the mean of nine wells, which were subjected to statistical analysis.
Definition of CIMP
According to the previously reported CIMP, which was defined by average of number of methylated genes per tumor, 28, 29 we classified it into two categories, including CIMP positive with at least three methylated genes and CIMP negative with less than three methylated genes.
Statistical Analysis
Chi-square test and Fisher exact test were used to evaluate the correlation between two different categories. Logistic regression was performed to assess odds ratios (ORs) and 95% confidence intervals, which were adjusted for gender, age, and smoking status, using STATA version 10.0 software package (StataCorp LP, College Station, TX). The sensitivity, specificity, positive predictive value, and accuracy for hOGG1, SEMA3B, RASSF1A, and 3pCIMP were calculated using the 2 ϫ 2 contingency table. Statistical differences were considered to be significant at p Ͻ 0.05. Data analysis was performed using SigmaStat software (Systat Software, San Jose, CA) and SPSS version 11.5 software package (SPSS Inc, Chicago, IL).
RESULTS
Relationship Between 3pCIMP and NSCLC Cell Proliferation
To determine whether 3pCIMP plays an important role in the proliferation of NSCLC cells, we performed DNA demethylation and MTT analyses and 3pCIMP evaluation on four NSCLC cell lines. As illustrated in Figure 1 , SPC-A-1 and A549 presented 3pCIMP positive before (day 1) and after (days 5 and 7) treatment of demethylation agent 5-aza-CdR, respectively. However, 95-D and LTEPa-2 showed 3pCIMP negative after (day 7) 5-aza-CdR treatment, albeit that they presented 3pCIMP positive after (day 5) demethylation treatment.
Meanwhile, we examined the effect of demethylation treatment on cell proliferation in these NSCLC cell lines. As shown in Figure 2 , cell proliferation was significantly decreased in 95-D and LTEP-a-2 on day 7, but not in SPC-A-1 and A549. These findings were compatible with 3pCIMP evaluation (Figure 1 ), indicating that 3pCIMP status could play an important role in NSCLC cell proliferation. 5-azaCdR treatment is a currently accepted system to investigate effects of hypomethylation, although this compound is recognized to be capable of inducing other cellular effects. 30 
Methylation Profile of Multiple Genes on 3p in PBMC From NSCLC Patients
Methylation profile for PBMC specimens from 80 NSCLC patients and 80 controls was determined using MSP method for six TSGs on 3p, including hOGG1, RAR-B, SEMA3B, RASSF1A, BLU, and FHIT. Representative bands for MSP analysis were exemplified in Figure 3 , and the detailed frequency distribution of aberrant methylation for each gene was seen in Figure 4 . With respect to NSCLC, the frequency of promoter methylation of the gene was 22.5% for hOGG1, 20.0% for RAR-B, 91.3% for SEMA3B, 20.0% for RASSF1A, 48.8% for BLU, and 23.8% for FHIT, respectively. By contrast, lower frequencies of methylation for hOGG1 (7.5%), RAR-B (8.8%), SEMA3B (47.5%), and RASSF1A (2.5%) were found in controls. A significant difference in methylation status for hOGG1, SEMA3B, and RASSF1A was found between PBMC from NSCLC patients versus PBMC from controls (p ϭ 0.02, p Ͻ 0.001, and p ϭ 0.001, respectively) ( Figure 5 ). (Table 1) . Using a chi-square test statistical analysis, we found that 3pCIMP status was significantly associated with NSCLC and normal blood samples ( 2 df ϭ 1 ϭ28.0, p Ͻ 0.001).
Frequency of 3pCIMP in PBMC From NSCLC Patients and Normal Blood Samples
3pCIMP of PBMC in Association with Increased Risk for NSCLC
In this study, we examined the relation of 3pCIMP status to clinical characteristics of NSCLC ( Table 2) . As a result, no significant association between 3pCIMP status and multiple clinical factors, including age, sex, smoking history, differentiation, tumor node metastasis stage, and histologic stratification was found (p Ͼ 0.05). To determine whether the presence of 3pCIMP has an effect on increased risk of NSCLC, we performed logistic regression to assess the ORs in the paired cohort. Consequently, methylation of hOGG1, SEMA3B, and RASSF1A, the gene pair hOGG1 and SEMA3B, hOGG1 and RASSF1A, and SEMA3B and RASSF1A was observed to increase significantly risk of NSCLC when compared with methylation-free ones (3.72-fold, p ϭ 0.02; 7.97-fold, p Ͻ 0.001; 4.49-fold, p ϭ 0.001; 9.95-fold, p Ͻ 0.001; infinite folds, p ϭ 0.02; 10.00-fold, p ϭ 0.001, respectively). More intriguingly, we found that 3pCIMP positive carriers had a 12.79-fold increased risk of developing NSCLC (adjusted OR, 12.8; 95% confidence interval, 4.38 -37.4, p Ͻ 0.001) in Chinese population ( Table 3 ).
Given that these DNA methylation marker candidates (listed in Table 4 ) seem to associate preferentially with increased risk of NSCLC in Chinese population, we compared the differences in their sensitivity and specificity for diagnosis of NSCLC. As summarized in Table 4 , the speci- ficity for SEMA3B (52.5%) and its combinations (47.5% and 52.5%) was much lower than hOGG1 (92.5%), RASSF1A (97.5%), the gene pair hOGG1 and RASSF1A (90.0%), and 3pCIMP (93.8%), although the sensitivity for SEMA3B (91.3%) and its combinations (92.5% and 91.3%) was much higher than hOGG1 (22.5%), RASSF1A (20.0%), the gene pair hOGG1 and RASSF1A (32.5%), and 3pCIMP (43.8%). Moreover, the positive predictive value and overall accuracy for 3pCIMP (87.5% and 68.8%) were relatively higher compared with a majority of DNA methylation marker candidates. Taken together, 3pCIMP ranks first among these potential DNA methylation markers for NSCLC carcinogenesis.
DISCUSSION
Reliable markers for NSCLC are still lacking, even though more efforts on discovering them have been made. 6 Improved understanding of molecular events, including epigenetic silencing of genes, may help to identify a panel of early tumor markers. 31, 32 Epigenetic silencing of TSGs via promoter hypermethylation has been found to correlate with the initiation and progression of various types of cancers, including lung cancer. 33, 34 3p may harbor multiple TSGs, which are involved in the early stages of bronchial carcinogenesis. 35 However, no evidence for association of PBMC epigenetic changes regarding TSGs on 3p with increased risk of NSCLC has been reported. Therefore, in this study, we focused on identifying the presence of 3pCIMP in NSCLC PBMC and assessing an association between PBMC 3pCIMP and the predisposition to NSCLC.
In an effort to validate first the biologic function of 3pCIMP, we performed MTT, 3pCIMP and demethylation analyses in four NSCLC cell lines and found different 3pCIMP status (either positive or negative) compatible with differentiately proliferated changes of NSCLC cells (either preserved or decreased), suggesting that 3pCIMP could function as an epigenetic silencing of TSGs in pathogenesis of NSCLC. These findings are consistent with those from our recently available study 8 of NSCLC tissues that noted a significant association between somatic 3pCIMP and development of NSCLC. Given the fact that methylated status of a CpG site is more stably inherited than unmethylated status 36 and that the best-known epigenetic marker is DNA methyl- ation, 37 we hypothesize that 3pCIMP might be emerging as a promising risk factor of NSCLC.
On the basis of what we observed earlier, additional studies are needed to address the question of whether 3pCIMP could contribute to increased risk of developing NSCLC. By using a population-based investigation, we found that the frequency of PBMC methylation for six TSGs promoter ranged from 20.0% for RAR-B (or RASSF1A) to 91.3% for SEMA3B. Although 3p TSG methylation is frequent in NSCLC PBMC, we cannot exclude the possibility that the detected TSG methylation is derived from circulating tumor cells in the peripheral blood. As summarized in our recently published article in Lung Cancer, 8 the frequencies of methylation for hOGG1, RAR-B, SEMA3B, RASSF1A, BLU, and FHIT in 60 NSCLC tumors are 65%, 50%, 57%, 67%, 65%, and 47%, respectively, showing that the methylation frequency for hOGG1, RAR-B, RASSF1A, BLU, and FHIT was far lower in NSCLC PBMC than paired NSCLC tissues. Especially, the frequency for VHL and hMLH1 that were not considered as contributing to PBMC 3pCIMP was zero in all subjects, including NSCLC patients and controls (data not shown). Despite of discrepant frequencies between our report and Seng et al. (hMLH1 in 12.0% and 35.7% of NSCLC tumors, respectively), 8, 38 the results suggested that hMLH1 methylation could be a late event in NSCLC progression. More importantly, 3pCIMPϩ was found in 43.8% of NSCLC PBMC specimens but only in 6.3% of normal PBMC samples. More excitingly, 3pCIMP-positive carriers have a 12.8-fold increased risk of developing NSCLC in Chinese population, and combined analysis with sensitivity and specificity has shown that 3pCIMP might become preferentially a surrogate for other DNA methylation marker candidates of NSCLC, including hOGG1, SEMA3B, and RASSF1A.
Although CIMP etiology remains elusive, it exists in several malignant solid tumors. 16 Meanwhile, the correlation of CIMP with clinicopathologic factors in various human cancers was well established. 39 -41 However, we did not find an association between 3pCIMP and multiple clinical factors, including age, sex, smoking history, differentiation, tumor node metastasis stage, and histologic stratification of NSCLC, which was in accordance with the data from Suzuki et al. 17 The results demonstrate that 3pCIMP could be in relation to NSCLC initiation rather than progression. Considering that treatment with demethylating agents can restore gene expression of inactivating TSGs, 42 administration of demethylating agents may become an ideal candidate for individuals with 3pCIMP positive to decrease risk of developing NSCLC.
In conclusion, we provide strong evidence of an association between PBMC 3pCIMP and risk for NSCLC, which supports the suggestion from Russo et al. 19 that peripheral lymphocytes could potentially be used as a surrogate for bronchial epithelial cells to detect altered DNA methylation in development and progression of lung cancer. Better understanding of 3pCIMP may provide new insight into cancer prevention and therapeutic interventions. 
